Skip to main
SYRE

SYRE Stock Forecast & Price Target

SYRE Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 62%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spyre Therapeutics is poised to experience significant growth as it advances multiple anti-TL1A antibodies through clinical trials, with promising results in UC and potential for combination therapy. The company's platform trial and diverse pipeline highlight its potential for success in addressing the unmet need for innovative treatments in IBD and other immune-mediated diseases. Additionally, its strategic approach to co-formulating mAbs with existing drugs could lead to a competitive advantage and higher market demand. With a current valuation of $98 per share based on SOTP analysis, Spyre Therapeutics presents a compelling investment opportunity in the biotechnology sector.

Bears say

Spyre Therapeutics is in the clinical stages of developing treatments for inflammatory bowel diseases and rheumatic diseases with potential to be best-in-class due to their extended half-life antibodies and multiple targeted MOAs. However, with a risk of unexpected outcomes and a lack of established class leaders in the market, the company faces hurdles in achieving commercial success especially in the competitive markets for its product candidates, leading to a negative outlook on its stock.

SYRE has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 62% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spyre Therapeutics Inc (SYRE) Forecast

Analysts have given SYRE a Strong Buy based on their latest research and market trends.

According to 13 analysts, SYRE has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spyre Therapeutics Inc (SYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.